CoChat

Therapeutic implication of vascular endothelial growth factor receptor-1 (VEGFR-1) targeting in cancer cells and tumor microenvironment by competitive and non-competitive inhibitors

Lacal, Pedro Miguel, Graziani, Grazia · 2018 · Pharmacological Research
Cited by 177

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

The vascular endothelial growth factor receptor‐1 (VEGFR‐1) is a tyrosine kinase receptor for VEGF‐A, VEGF‐B, and placental growth factor (PlGF) ligands that is expressed in endothelial, myelomonocytic and tumor cells. VEGF‐B and PlGF exclusively bind to VEGFR‐1, whereas VEGF‐A also binds to VEGFR‐2. At variance with VEGFR‐2, VEGFR‐1 does not play a relevant role in physiological angiogenesis in the adult, while it is important in tumor‐associated angiogenesis. VEGFR‐1 and PlGF are expressed in a variety of tumors, promote invasiveness and contribute to resistance to anti‐VEGF‐A therapy. The currently approved antiangiogenic therapies for the treatment of a variety of solid tumors hamper VEGF‐A signaling mediated by both VEGFR‐2 and VEGFR‐1 [i.e., the monoclonal antibody (mAb) anti‐VEGF‐A bevacizumab, the chimeric molecule aflibercept and several small molecule tyrosine kinase inhibitors] or exclusively by VEGFR‐2 (i.e., the mAb anti‐VEGFR‐2 ramucirumab). However, molecules that interfere with VEGF‐A/VEGFR‐2 signaling determine severe adverse effects due to inhibition of physiological angiogenesis and their efficacy is hampered by tumor infiltration of protumoral myeloid cells. Blockade of VEGFR‐1 may exert anti‐tumor activity by multiple mechanisms: a) inhibition of tumor‐associated angiogenesis; b) reduction of myeloid progenitor mobilization and tumor infiltration by VEGFR‐1 expressing M2 macrophages, which contribute to tumor progression and spreading; c) inhibition of invasiveness, vasculogenic mimicry and survival of VEGFR‐1 positive tumor cells. As a consequence of these properties, molecules targeting VEGFR‐1 are expected to produce less adverse effects and to counteract resistance towards anti‐VEGF‐A therapies. More interestingly, selective VEGFR‐1 inhibition might enhance the efficacy of immunotherapy with immune checkpoint inhibitors. In this review, we will examine the experimental evidence available so far that supports targeting VEGFR‐1 signal transduction pathway for cancer treatment by competitive inhibitors that prevent growth factor interaction with the receptor and non‐competitive inhibitors that hamper receptor activation without affecting ligand binding.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.phrs.2018.08.023

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 177

Metadata

Authors
Lacal, P. M., & Graziani, G.
Venue
Pharmacological Research
Publisher
Elsevier BV
Published
2018-10
Volume
136
Pages
97-107
ISSN
1043-6618 (ISSN-L)
OpenAlex
W2888829038
Cited by
177
References
10
FWCI
6.91
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.